Effects of enteric-coated, low-dose aspirin on parameters of platelet function
Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Science Ltd ; 2002 |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2002 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Alimentary pharmacology & therapeutics - Oxford : Blackwell Science, 1987, 16(2002), 9, Seite 0 |
| Übergeordnetes Werk: |
volume:16 ; year:2002 ; number:9 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1046/j.1365-2036.2002.01332.x |
|---|
| Katalog-ID: |
NLEJ242205070 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242205070 | ||
| 003 | DE-627 | ||
| 005 | 20230506180916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2002 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1046/j.1365-2036.2002.01332.x |2 doi | |
| 035 | |a (DE-627)NLEJ242205070 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 245 | 1 | 0 | |a Effects of enteric-coated, low-dose aspirin on parameters of platelet function |
| 264 | 1 | |a Oxford, UK |b Blackwell Science Ltd |c 2002 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating. | ||
| 533 | |d 2002 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2002|||||||||| | ||
| 700 | 1 | |a Van Hecken, A. |4 oth | |
| 700 | 1 | |a Juliano, M. L. |4 oth | |
| 700 | 1 | |a Depré, M. |4 oth | |
| 700 | 1 | |a De Lepeleire, I. |4 oth | |
| 700 | 1 | |a Arnout, J. |4 oth | |
| 700 | 1 | |a Dynder, A. |4 oth | |
| 700 | 1 | |a Wildonger, L. |4 oth | |
| 700 | 1 | |a Petty, K. J. |4 oth | |
| 700 | 1 | |a Gottesdiener, K. |4 oth | |
| 700 | 1 | |a De Hoon, J. N. |4 oth | |
| 773 | 0 | 8 | |i In |t Alimentary pharmacology & therapeutics |d Oxford : Blackwell Science, 1987 |g 16(2002), 9, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926529 |w (DE-600)2003094-0 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2002 |g number:9 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1046/j.1365-2036.2002.01332.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2002 |e 9 |h 0 | ||
| matchkey_str |
article:13652036:2002----::fetoetrcotdodsaprnnaaees |
|---|---|
| hierarchy_sort_str |
2002 |
| publishDate |
2002 |
| allfields |
10.1046/j.1365-2036.2002.01332.x doi (DE-627)NLEJ242205070 DE-627 ger DE-627 rakwb Effects of enteric-coated, low-dose aspirin on parameters of platelet function Oxford, UK Blackwell Science Ltd 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Van Hecken, A. oth Juliano, M. L. oth Depré, M. oth De Lepeleire, I. oth Arnout, J. oth Dynder, A. oth Wildonger, L. oth Petty, K. J. oth Gottesdiener, K. oth De Hoon, J. N. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), 9, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 number:9 pages:0 http://dx.doi.org/10.1046/j.1365-2036.2002.01332.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 9 0 |
| spelling |
10.1046/j.1365-2036.2002.01332.x doi (DE-627)NLEJ242205070 DE-627 ger DE-627 rakwb Effects of enteric-coated, low-dose aspirin on parameters of platelet function Oxford, UK Blackwell Science Ltd 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Van Hecken, A. oth Juliano, M. L. oth Depré, M. oth De Lepeleire, I. oth Arnout, J. oth Dynder, A. oth Wildonger, L. oth Petty, K. J. oth Gottesdiener, K. oth De Hoon, J. N. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), 9, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 number:9 pages:0 http://dx.doi.org/10.1046/j.1365-2036.2002.01332.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 9 0 |
| allfields_unstemmed |
10.1046/j.1365-2036.2002.01332.x doi (DE-627)NLEJ242205070 DE-627 ger DE-627 rakwb Effects of enteric-coated, low-dose aspirin on parameters of platelet function Oxford, UK Blackwell Science Ltd 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Van Hecken, A. oth Juliano, M. L. oth Depré, M. oth De Lepeleire, I. oth Arnout, J. oth Dynder, A. oth Wildonger, L. oth Petty, K. J. oth Gottesdiener, K. oth De Hoon, J. N. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), 9, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 number:9 pages:0 http://dx.doi.org/10.1046/j.1365-2036.2002.01332.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 9 0 |
| allfieldsGer |
10.1046/j.1365-2036.2002.01332.x doi (DE-627)NLEJ242205070 DE-627 ger DE-627 rakwb Effects of enteric-coated, low-dose aspirin on parameters of platelet function Oxford, UK Blackwell Science Ltd 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Van Hecken, A. oth Juliano, M. L. oth Depré, M. oth De Lepeleire, I. oth Arnout, J. oth Dynder, A. oth Wildonger, L. oth Petty, K. J. oth Gottesdiener, K. oth De Hoon, J. N. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), 9, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 number:9 pages:0 http://dx.doi.org/10.1046/j.1365-2036.2002.01332.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 9 0 |
| allfieldsSound |
10.1046/j.1365-2036.2002.01332.x doi (DE-627)NLEJ242205070 DE-627 ger DE-627 rakwb Effects of enteric-coated, low-dose aspirin on parameters of platelet function Oxford, UK Blackwell Science Ltd 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Van Hecken, A. oth Juliano, M. L. oth Depré, M. oth De Lepeleire, I. oth Arnout, J. oth Dynder, A. oth Wildonger, L. oth Petty, K. J. oth Gottesdiener, K. oth De Hoon, J. N. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), 9, Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 number:9 pages:0 http://dx.doi.org/10.1046/j.1365-2036.2002.01332.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 9 0 |
| source |
In Alimentary pharmacology & therapeutics 16(2002), 9, Seite 0 volume:16 year:2002 number:9 pages:0 |
| sourceStr |
In Alimentary pharmacology & therapeutics 16(2002), 9, Seite 0 volume:16 year:2002 number:9 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Alimentary pharmacology & therapeutics |
| authorswithroles_txt_mv |
Van Hecken, A. @@oth@@ Juliano, M. L. @@oth@@ Depré, M. @@oth@@ De Lepeleire, I. @@oth@@ Arnout, J. @@oth@@ Dynder, A. @@oth@@ Wildonger, L. @@oth@@ Petty, K. J. @@oth@@ Gottesdiener, K. @@oth@@ De Hoon, J. N. @@oth@@ |
| publishDateDaySort_date |
2002-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926529 |
| id |
NLEJ242205070 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242205070</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506180916.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2002 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-2036.2002.01332.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242205070</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effects of enteric-coated, low-dose aspirin on parameters of platelet function</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Van Hecken, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Juliano, M. L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Depré, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Lepeleire, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnout, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dynder, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wildonger, L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Petty, K. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gottesdiener, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Hoon, J. N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Alimentary pharmacology & therapeutics</subfield><subfield code="d">Oxford : Blackwell Science, 1987</subfield><subfield code="g">16(2002), 9, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926529</subfield><subfield code="w">(DE-600)2003094-0</subfield><subfield code="x">1365-2036</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2002</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-2036.2002.01332.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2002</subfield><subfield code="e">9</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926529 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1365-2036 |
| topic_title |
Effects of enteric-coated, low-dose aspirin on parameters of platelet function |
| publisher |
Blackwell Science Ltd |
| publisherStr |
Blackwell Science Ltd |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
h a v ha hav m l j ml mlj m d md l i d li lid j a ja a d ad l w lw k j p kj kjp k g kg h j n d hjn hjnd |
| hierarchy_parent_title |
Alimentary pharmacology & therapeutics |
| hierarchy_parent_id |
NLEJ243926529 |
| hierarchy_top_title |
Alimentary pharmacology & therapeutics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926529 (DE-600)2003094-0 |
| title |
Effects of enteric-coated, low-dose aspirin on parameters of platelet function |
| spellingShingle |
Effects of enteric-coated, low-dose aspirin on parameters of platelet function |
| ctrlnum |
(DE-627)NLEJ242205070 |
| title_full |
Effects of enteric-coated, low-dose aspirin on parameters of platelet function |
| journal |
Alimentary pharmacology & therapeutics |
| journalStr |
Alimentary pharmacology & therapeutics |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2002 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| container_volume |
16 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| doi_str_mv |
10.1046/j.1365-2036.2002.01332.x |
| title_sort |
effects of enteric-coated, low-dose aspirin on parameters of platelet function |
| title_auth |
Effects of enteric-coated, low-dose aspirin on parameters of platelet function |
| abstract |
Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating. |
| abstractGer |
Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating. |
| abstract_unstemmed |
Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
9 |
| title_short |
Effects of enteric-coated, low-dose aspirin on parameters of platelet function |
| url |
http://dx.doi.org/10.1046/j.1365-2036.2002.01332.x |
| remote_bool |
true |
| author2 |
Van Hecken, A. Juliano, M. L. Depré, M. De Lepeleire, I. Arnout, J. Dynder, A. Wildonger, L. Petty, K. J. Gottesdiener, K. De Hoon, J. N. |
| author2Str |
Van Hecken, A. Juliano, M. L. Depré, M. De Lepeleire, I. Arnout, J. Dynder, A. Wildonger, L. Petty, K. J. Gottesdiener, K. De Hoon, J. N. |
| ppnlink |
NLEJ243926529 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1046/j.1365-2036.2002.01332.x |
| up_date |
2024-07-06T01:12:31.786Z |
| _version_ |
1803790164204453888 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242205070</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506180916.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2002 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-2036.2002.01332.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242205070</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effects of enteric-coated, low-dose aspirin on parameters of platelet function</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background : Aspirin is widely used as an anti-thrombotic drug; however, it has been suggested that enteric-coated formulations of aspirin may be less bioavailable and less effective as anti-thrombotic agents.Aim : To assess the effect of a formulation of enteric-coated, low-dose (81 mg) aspirin on serum generated thromboxane B2 and platelet aggregation in healthy subjects.Methods : Twenty-four subjects participated in a double-blind, randomized, placebo-controlled, parallel-group, multiple-dose study. Twelve subjects in each of two groups received a daily oral dose of enteric-coated aspirin (81 mg) or matching placebo for 7 days. Serum thromboxane B2 and platelet aggregation (using 1 mm arachidonic acid and 1 µg/mL collagen as agonists) were measured 1–3 days prior to day 1, on day 1 (prior to therapy) and 4 h after the last dose on day 7.Results : After seven daily doses of enteric-coated aspirin, the mean percentage inhibition from baseline of ex vivo generated serum thromboxane B2 was 97.4%, compared with a 7.8% increase after placebo treatment. The mean percentage inhibition of arachidonic acid- and collagen-induced platelet aggregation was 97.9% and 70.9%, respectively, following enteric-coated aspirin, compared with − 1.0% and 2.7%, respectively, after placebo.Conclusions : The anti-platelet effects of multiple, daily, low-dose aspirin (as assessed by inhibition of serum thromboxane B2 and platelet aggregation) are not adversely affected by enteric coating.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Van Hecken, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Juliano, M. L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Depré, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Lepeleire, I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arnout, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dynder, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wildonger, L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Petty, K. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gottesdiener, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">De Hoon, J. N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Alimentary pharmacology & therapeutics</subfield><subfield code="d">Oxford : Blackwell Science, 1987</subfield><subfield code="g">16(2002), 9, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926529</subfield><subfield code="w">(DE-600)2003094-0</subfield><subfield code="x">1365-2036</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2002</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-2036.2002.01332.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2002</subfield><subfield code="e">9</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.401618 |